Randall Moreadith, Serina Therapeutics, Inc.'s Chief Scientific Officer, completed the sale of 6,500 shares of the company's common stock on January 28, 2026. The shares were sold at a weighted average price of $3.567, producing total proceeds of $23,185. Reported execution prices for the trades fell between $3.55 and $3.59 per share.
On that same day, Moreadith exercised stock options to acquire 6,500 shares at an exercise price of $0.06 per share, for a total cost of $390, and then sold those shares as described above. After the transactions, the CSO directly holds zero shares of Serina Therapeutics.
The company's share price was noted at $3.74 following the transaction, significantly lower than its 52-week high of $7.92. Available analysis places the stock slightly above its Fair Value. Over the previous six months the stock has declined 54.4% in price, even as the firm reports a balance sheet with a stronger cash position than debt.
Serina Therapeutics is a micro-cap biotechnology company with a market capitalization of $39.56 million. Recent analytical commentary has rated the company’s overall financial health as "WEAK" and flagged that it is "quickly burning through cash," an observation listed among other analytical notes available for deeper inspection of the company's prospects.
Alongside the insider transaction and financial observations, Serina has recorded several operational and governance developments. The company received regulatory clearance to proceed with an Investigational New Drug application for SER-252, a therapeutic candidate targeting advanced Parkinson's disease. That clearance enables the start of a Phase 1b clinical study, and site-level activities are already under way in Australia to support the global program.
At the same time, Serina has received a notice from the New York Stock Exchange indicating the company does not meet continued listing criteria. The notice cites stockholders' equity of $1.6 million and net losses in three of the last four fiscal years as the bases for the deficiency.
Corporate governance changes were finalized at the company’s 2025 Annual Meeting of Stockholders. Shareholders elected Steve Ledger and Karen J. Wilson to the board of directors; both directors will serve through the 2028 Annual Meeting.
What happened
- CSO Randall Moreadith exercised options for 6,500 shares at $0.06 per share ($390), then sold 6,500 shares on January 28, 2026, at a weighted average of $3.567 for $23,185.
- Following the sale, Moreadith holds no direct shares in Serina Therapeutics.
- Share price was reported at $3.74, versus a 52-week high of $7.92; six-month decline totaled 54.4%.
Context and company condition
- Market capitalization stands at $39.56 million.
- Analytical assessments characterize the company’s financial health as "WEAK" and indicate a rapid cash burn profile.
- The company has both clinical progress and regulatory pressure: an IND clearance for SER-252 and an NYSE notice for not meeting listing criteria.
The transactions, corporate updates and regulatory notices together outline a complex near-term picture for Serina Therapeutics: clinical advancement in a Parkinson's program alongside financial and listing challenges and recent board-level changes.